Metabolic characteristics of Tanshinone I in human liver microsomes and S9 subcellular fractions

References

• Barr JT, Jones JP. (2011). Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 39:2381–6.
   PubMed Web of Science ®Google Scholar
• Cai Y, Zhang WJ, Chen ZR, et al. (2016). Recent insights into the biological activities and drug delivery systems of tanshinones. Int J Nanomedicine 11:121–30.
   PubMed Web of Science ®Google Scholar
• Chen BH, Park JH, Cho JH, et al. (2016). Tanshinone I enhances neurogenesis in the mouse hippocampal dentate gyrus via increasing Wnt-3, phosphorylated glycogen synthase kinase-3b and b-catenin immunoreactivities. Neurochem Res 41:1958–68.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Wang L, Iacono L, et al. (2018). Clinical significance of CYP2C19 polymorphisms on the metabolism and pharmacokinetics of 11β-hydroxysteroid dehydrogenase type-1 inhibitor BMS-823778. Br J Clin Pharmacol 84:130–41.
   PubMed Web of Science ®Google Scholar
• Crouch RD, Blobaum AL, Felts AS, et al. (2017). Species-specific involvement of aldehyde oxidase and xanthine oxidase in the metabolism of the pyrimidine-containing mGlu5-negative allosteric modulator VU0424238 (Auglurant). Drug Metab Dispos 45:1245–59.
   PubMed Web of Science ®Google Scholar
• Cubitt HE, Houston JB, Galetin A. (2011). Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data. Drug Metab Dispos 39:864–73.
   PubMed Web of Science ®Google Scholar
• Danielson L, Ernster L, Ljunggren M. (1960). Selective extraction of DT diaphorase from mitochondria and microsomes. Acta Chem Scand 14:1837–8.
   Google Scholar
• Diamond S, Boer J, Maduskuie TP, et al. (2010). Species-specific metabolism of SGX523 by aldehyde oxidase and the toxicological implications. Drug Metab Dispos 38:1277–85.
   PubMed Web of Science ®Google Scholar
• Ei-Serafi I, Terelius Y, Abedi-Valugerdi M, et al. (2017). Flavin-containing monooxygenase 3 (FMO3) role in busulphan metabolic pathway. PLoS One 12:e0187294
   PubMed Web of Science ®Google Scholar
• Feng Y, Huang SL, Dou W, et al. (2010). Emodin, a natural product, selectively inhibits 11b-hydroxysteroid dehydrogenase type 1 and ameliorates metabolic disorder in diet-induced obese mice. Br J Pharmacol 161:113–26.
   PubMed Web of Science ®Google Scholar
• Hao HP, Wang GJ, Cui N, et al. (2007). Identification of a novel intestinal first pass metabolic pathway: NQO1 mediated quinone reduction and subsequent glucuronidation. Curr Drug Metab 8:137–49.
   PubMed Web of Science ®Google Scholar
• Harbourt DE, Fallon JK, Ito S, et al. (2012). Quantification of human uridine-diphosphate glucuronosyl transferase (UGT) 1A isoforms in liver, intestine and kidney using nanoLC-MS/MS. Anal Chem 84:98–105.
   PubMed Web of Science ®Google Scholar
• Chen J, Liu D, Zheng X, et al. (2015). Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling. Expert Opin Drug Metab Toxicol 11:857–68.
   PubMed Web of Science ®Google Scholar
• Jing XP, Xu YC, Cheng WW, et al. (2016). Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers. Cancer Chemother Pharmacol 77:1171–81.
   PubMed Web of Science ®Google Scholar
• Li G, Huang K, Nikolic D, van Breemen RB. (2015). High-throughput cytochrome P450 cocktail inhibition assay for assessing drug-drug and drug-botanical interactions. Drug Metab Dispos 43:1670–8.
   PubMed Web of Science ®Google Scholar
• Liu J, Wu JL, Wang XR, Cai ZW. (2007). Study of the phase I and phase II metabolism of a mixture containing multiple tanshinones using liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 21:2992–8.
   PubMedGoogle Scholar
• Obach RS, Baxter JG, Liston TE, et al. (1997). The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp 283:46–58.
   PubMed Web of Science ®Google Scholar
• de Oliveira MR, Fürstenau CR, de Souza ICC, da Costa FG. (2017). Tanshinone I attenuates the effects of a challenge with H2O2 on the functions of tricarboxylic acid cycle and respiratory chain in SH-SY5Y cells. Mol Neurobiol 54:7858–68.
   PubMed Web of Science ®Google Scholar
• Park EJ, Zhao YZ, Kim YC, Sohn DH. (2009). Preventive effects of a purified extract isolated from Salvia miltiorrhiza enriched with tanshinone I, tanshinone IIA and cryptotanshinone on hepatocyte injury in vitro and in vivo. Food Chem Toxicol 47:2742–8.
   PubMed Web of Science ®Google Scholar
• Sohlenius-Sternbeck A-K, Afzelius L, Prusis P, et al. (2010). Evaluation of the human prediction of clearance from hepatocyte and microsome intrinsic clearance for 52 drug compounds. Xenobiotica 40:637–49.
   PubMed Web of Science ®Google Scholar
• Tassaneeyakul W, Birkett DJ, Veronese ME, et al. (1993). Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J Pharmacol Exp Ther 265:401–7.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. (2004). Drug interaction studies – study design, data analysis, and implications for dosing and labeling.
   Google Scholar
• Venkatakrishnan K, von Moltke LL, Court MH, et al. (2000). Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches. Drug Metab Dispos 28:1493–504.
   PubMed Web of Science ®Google Scholar
• Vredenburg G, Elias NS, Venkataraman H, et al. (2014). Human NAD(P)H:quinone oxidoreductase 1 (NQO1)-mediated inactivation of reactive quinoneimine metabolites of diclofenac and mefenamic acid. Chem Res Toxicol 27:576–86.
   PubMed Web of Science ®Google Scholar
• Wang MW, Dai HX, Li XR, et al. (2010). Structural elucidation of metabolites of tanshinone I and its analogue dihydrotanshinone I in rats by HPLC-ESI-MSn. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci 878:915–24.
   PubMed Web of Science ®Google Scholar
• Wang SX, Jing HR, Yang HY, et al. (2015). Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease. J Ethnopharmacol 164:247–55.
   PubMed Web of Science ®Google Scholar
• Watanabe Y, Nakajima M, Yokoi T. (2002). Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos 30:1462–9.
   PubMed Web of Science ®Google Scholar
• Wu XM, Zhang QH, Guo JM, et al. (2017). Metabolism of F18, a derivative of calanolide A, in human liver microsomes and cytosol. Front Pharmacol 8:479.
   PubMed Web of Science ®Google Scholar
• Xing L, Tan ZR, Cheng JL, et al. (2017). Bioavailability and pharmacokinetic comparison of tanshinones between two formulations of Salvia miltiorrhiza in healthy volunteers. Sci Rep 7:4709–18.
   PubMed Web of Science ®Google Scholar